Aldana I - Search Results

1

Changes in UCP2, PPARgamma2, and c/EBPalpha gene expression induced by a neuropeptide Y (NPY) related receptor antagonist in overweight rats.

Margareto J, Rivero I, Monge A, Aldana I, Marti A, Martínez JA. Margareto J, et al. Among authors: aldana i. Nutr Neurosci. 2002 Feb;5(1):13-7. doi: 10.1080/10284150290007065. Nutr Neurosci. 2002. PMID: 11929193

2

A new NPY-antagonist strongly stimulates apoptosis and lipolysis on white adipocytes in an obesity model.

Margareto J, Aguado M, Osés-Prieto JA, Rivero I, Monge A, Aldana I, Marti A, Martínez JA. Margareto J, et al. Among authors: aldana i. Life Sci. 2000 Nov 24;68(1):99-107. doi: 10.1016/s0024-3205(00)00916-4. Life Sci. 2000. PMID: 11132250

3

Synthesis of new thiophene and benzo[b]thiophene hydrazide derivatives as human NPY Y(5) antagonists.

Galiano S, Erviti O, Pérez S, Moreno A, Juanenea L, Aldana I, Monge A. Galiano S, et al. Among authors: aldana i. Bioorg Med Chem Lett. 2004 Feb 9;14(3):597-9. doi: 10.1016/j.bmcl.2003.11.070. Bioorg Med Chem Lett. 2004. PMID: 14741250

4

Synthesis and evaluation of new arylsulfonamidomethylcyclohexyl derivatives as human neuropeptide Y Y5 receptor antagonists for the treatment of obesity.

Moreno A, Pérez S, Galiano S, Juanenea L, Erviti O, Frígola C, Aldana I, Monge A. Moreno A, et al. Among authors: aldana i. Eur J Med Chem. 2004 Jan;39(1):49-58. doi: 10.1016/j.ejmech.2003.10.001. Eur J Med Chem. 2004. PMID: 14987833

5

Synthesis and evaluation of new hydrazide derivatives as neuropeptide Y Y5 receptor antagonists for the treatment of obesity.

Juanenea L, Galiano S, Erviti O, Moreno A, Pérez S, Aldana I, Monge A. Juanenea L, et al. Among authors: aldana i. Bioorg Med Chem. 2004 Sep 1;12(17):4717-23. doi: 10.1016/j.bmc.2004.06.023. Bioorg Med Chem. 2004. PMID: 15358298

6

Novel human neuropeptide Y Y5 receptor antagonists for the treatment of obesity. Synthesis and biological evaluation of pyridine hydrazide derivatives.

Galiano S, Erviti O, Pérez S, Moreno A, Juanenea L, Aldana I, Monge A. Galiano S, et al. Among authors: aldana i. Arzneimittelforschung. 2005;55(2):81-5. doi: 10.1055/s-0031-1296827. Arzneimittelforschung. 2005. PMID: 15787274

7

Building a MCHR1 homology model provides insight into the receptor-antagonist contacts that are important for the development of new anti-obesity agents.

Cirauqui N, Schrey AK, Galiano S, Ceras J, Pérez-Silanes S, Aldana I, Monge A, Kühne R. Cirauqui N, et al. Among authors: aldana i. Bioorg Med Chem. 2010 Nov 1;18(21):7365-79. doi: 10.1016/j.bmc.2010.09.014. Epub 2010 Sep 15. Bioorg Med Chem. 2010. PMID: 20932767

8

New perhydro-1,4-oxazine derivatives of arylethanolamine with beta 3-adrenoceptor agonist activity.

Monge A, Aldana I, Cerecetto H, Rivero A, Del Barrio A, Perez R, Portillo M, Martinez A. Monge A, et al. Among authors: aldana i. Pharmazie. 1995 Nov;50(11):768-9. Pharmazie. 1995. PMID: 8570676 No abstract available.

9

Physico-chemical properties and stability of the new hypoxia-selective agent 7-chloro-3-[[N,N-dimethylamino)propyl]amino]-2-quinoxalinecarbonitrile 1,4-di-N-oxide hydrochloride.

Zamalloa E, Aldana I, Bachiller CM, Monge A. Zamalloa E, et al. Among authors: aldana i. Arzneimittelforschung. 1997 Jul;47(7):873-8. Arzneimittelforschung. 1997. PMID: 9272248

10

Determination of a new hypoxia selective agent from 2-quinoxalinecarbonitrile 1,4-di-N-oxides in plasma by high performance liquid chromatography.

Zamalloa E, Dios-Viéitez C, González-Peñas E, Monge A, Aldana I. Zamalloa E, et al. Among authors: aldana i. Arzneimittelforschung. 1997 Sep;47(9):1044-6. Arzneimittelforschung. 1997. PMID: 9342420

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

111 results

Search Page

Filters